# Understanding the effects of Universal Test and Treat on 1 longitudinal HIV care continuum outcomes among South African 2 youth: a retrospective cohort study 3 4 5 Lindsey M. Filiatreau<sup>1,2§</sup>, Jessie K. Edwards<sup>3</sup>, Nkosinathi Masilela<sup>4</sup>, F. Xavier Gómez-Olivé<sup>4</sup>, 6 Nicole Haberland<sup>5</sup>, Brian W. Pence<sup>3</sup>, Joanna Maselko<sup>3</sup>, Kathryn E. Muessig<sup>6</sup>, Chodziwadziwa 7 Whiteson Kabudula<sup>4</sup>, Mi-Suk Kang Dufour<sup>7</sup>, Sheri A. Lippman<sup>4,7</sup>, Kathleen Kahn<sup>4</sup>, and Audrey Pettifor<sup>3,4,8</sup> 8 9 10 1 Department of Psychiatry, School of Medicine, Washington University in St. Louis 11 2 International Center for Child Health and Development, Brown School, Washington University 12 in St. Louis 13 3 Department of Epidemiology, Gillings School of Global Public Health, University of North 14 Carolina at Chapel Hill, Chapel Hill, North Carolina, USA 15 4 MRC/Wits Rural Public Health and Health Transitions Research Unit (Agincourt), School of 16 Public Health, Faculty of Health Sciences, University of the Witwatersrand, South Africa 17 5 Population Council, New York, New York, USA 18 6 Department of Health Behavior, Gillings School of Global Public Health, University of North 19 Carolina at Chapel Hill, Chapel Hill, North Carolina, USA 20 7 Division of Prevention Science, Department of Medicine, University of California, San 21 Francisco, San Francisco, California, USA 22 8 Carolina Population Center, Chapel Hill, North Carolina, USA

0	$\mathbf{a}$
• )	-
	,

24 <sup>§</sup> Corresponding Author: Lindsey M. Filiatreau

25

- 26 Department of Psychiatry
- 27 660 S. Euclid Ave.
- 28 St. Louis, MO 63110
- 29 flindsey@wustl.edu
- 30 Phone: 502.827.3672
- 31 Fax: 314.935.8511

- 33 E-mail addresses of authors:
- 34 LMF: flindsey@wustl.edu
- 35 JKE: jessedwards@unc.edu
- 36 NM: Nkosinathi.masilela@wits.ac.za
- 37 FXG-O: f.gomez-olivecasas@wits.ac.za
- 38 NH: nhaberland@popcouncil.org
- 39 BWP: bpence@unc.edu
- 40 JM: jmaselko@unc.edu
- 41 KM: kmuessig@med.unc.edu
- 42 CWK: chodziwadziwa.kabudula@wits.ac.za
- 43 MKD: mi-suk@berkeley.edu
- 44 SAL: sheri.lippman@ucsf.edu
- 45 KK: Kathleen.kahn@wits.ac.za
- 46 AP: apettif@email.unc.edu

# 47 Abstract

48	Introduction: Little is known about when youth living with HIV (YLHIV) are most susceptible
49	to disengagement from HIV care. The longitudinal HIV care continuum is an underutilized tool
50	that can provide a holistic understanding of population-level HIV care trajectories and be used to
51	compare treatment outcomes across groups. We aimed to explore effects of the Universal Test
52	and Treat policy (UTT) on longitudinal care outcomes among South African youth living with
53	HIV (YLHIV) and identify temporally precise opportunities for re-engaging this priority
54	population.
55	
56	Methods: Using medical record and census data, we conducted a retrospective cohort study
57	among youth aged 18-24 newly diagnosed with HIV between August 2015 and December 2018
58	in nine health care facilities in rural South Africa. We used weighted Fine and Grey sub-
59	distribution proportional hazards models to characterize longitudinal care continuum outcomes in
60	the population overall and stratified by treatment era of diagnosis. We estimated the proportion
61	of individuals in each stage of the continuum over time and the mean time spent in each stage in
62	the first year following diagnosis. Estimates for the two groups were compared using differences
63	(diagnosis pre-UTT=referent).
64	

Results: A total of 420 YLHIV were included. By the end of the first year following diagnosis,
just 23% of individuals had no 90-or-more-day lapse in care and were virally suppressed. Those
diagnosed in the UTT era spent less time as ART-naïve (mean difference=-19.3 days; 95% CI: 27.7, -10.9) and more time virally suppressed (mean difference=17.7; 95% CI: 1.0, 34.4)
compared to those diagnosed pre-UTT adoption. Most individuals who were diagnosed in the

70 UTT era and experienced a 90-or-more-day lapse in care disengaged between diagnosis and

71 linkage to care or ART initiation and viral suppression.

72

- 73 Conclusions: Implementation of UTT yielded modest improvements in time spent on ART and
- virally suppressed among South African YLHIV. However, meeting UNAIDS' 95-95-95 targets
- remains a challenge in this priority population. Retention in care and re-engagement
- 76 interventions that can be implemented between diagnosis and linkage to care (e.g., longitudinal
- counseling following diagnosis) or ART initiation and viral suppression may be particularly
- 78 important to improving treatment outcomes among South African YLHIV.

79

80

81 **Keywords:** Universal Test and Treat; HIV care continuum; youth living with HIV; South Africa;

82 viral suppression; retention in care

# 83 Introduction

84	Traditional methods for monitoring HIV treatment outcomes often fail to capture the complexity
85	of the processes of engagement, disengagement, and reengagement in care that individuals living
86	with HIV may cycle through over time. The longitudinal HIV care continuum framework is an
87	underutilized alternative to these approaches that can provide a more nuanced picture of
88	population-level outcomes over time (1,2). This tool may be particularly useful for assessing
89	holistic differences in treatment outcomes in distinct groups and can be harnessed to identify
90	specific gaps in treatment and care services at precise time points following diagnosis (1,3).
91	
92	Existing evidence suggests youth living with HIV (YLHIV) experience worse HIV treatment
92 93	Existing evidence suggests youth living with HIV (YLHIV) experience worse HIV treatment outcomes at each stage in the HIV care continuum compared to adults (4–8). In sub-Saharan
93	outcomes at each stage in the HIV care continuum compared to adults (4–8). In sub-Saharan
93 94	outcomes at each stage in the HIV care continuum compared to adults (4–8). In sub-Saharan Africa, YLHIV are particularly vulnerable to suboptimal treatment outcomes (7,9). A 2016 meta-
93 94 95	outcomes at each stage in the HIV care continuum compared to adults (4–8). In sub-Saharan Africa, YLHIV are particularly vulnerable to suboptimal treatment outcomes (7,9). A 2016 meta- analysis conducted by Zanoni and colleagues found that just 14% of South African YLHIV aged
93 94 95 96	outcomes at each stage in the HIV care continuum compared to adults (4–8). In sub-Saharan Africa, YLHIV are particularly vulnerable to suboptimal treatment outcomes (7,9). A 2016 meta- analysis conducted by Zanoni and colleagues found that just 14% of South African YLHIV aged 15 to 24 accessed antiretroviral treatment (ART) (10). Among those who accessed treatment, an

In line with the World Health Organization's treatment recommendations, the South African government adopted a Universal Test and Treat (UTT) policy in September 2016 (11). This policy increased access to ART for all people living with HIV regardless of clinical stage and improved a number of HIV treatment outcomes among South African adults living with HIV (12). However, some studies suggest UTT increased attrition from care following treatment initiation (13). While little is known about the specific effects of this policy on treatment

outcomes among YLHIV specifically, current data suggest poor retention in care and viralsuppression persist in the population (14,15).

108

109 Addressing barriers to sustained engagement in care among YLHIV is critical if we are to end 110 the HIV epidemic by 2030 (8,16). Yet, a limited number of studies have identified temporally 111 precise opportunities for re-engaging this population following lapses in care (6). We draw on 112 the longitudinal HIV care continuum framework to estimate the proportion of individuals in each 113 stage of the HIV care continuum over time and the restricted mean time spent in each stage 114 during the first year following diagnosis in a population of YLHIV in rural South Africa. We 115 compare these outcomes by treatment era of diagnosis-- pre- or post-UTT implementation-- to 116 illuminate the effects of this policy on longitudinal care trajectories and opportunities for re-117 engaging this priority population under current treatment recommendations.

118

### 119 Methods

### 120 Study site

121 This study was conducted in the Agincourt Health and Socio-Demographic Surveillance System 122 study area (HDSS) in rural Mpumalanga Province, South Africa (17). This area is approximately 123 500 kilometers northeast of Johannesburg (17) and home to nearly 120,000 individuals (18). An 124 estimated 27% of young women and 6% of young men ages 20 to 24 in this area are living with 125 HIV (19). Access to public sector services and economic opportunities post-schooling is limited, 126 contributing to a high degree of work-related migration, particularly among youth exiting the 127 school system (20). Nine publicly funded health care facilities provide medical services to a 128 majority of study area residents. Within these facilities, access to primary health care and ART is

free of charge. However, patient wait times often exceed national standards and there is limitedto no differentiated care for young people (21).

131

### 132 Study population

133 We extracted data for all individuals aged 18 to 24 with a recorded HIV diagnosis in the HDSS-

134 Clinic Link System (n=685), described in further detail below, between August 1<sup>st</sup>, 2015, and

135 December 31<sup>st</sup>, 2018. Individuals who were not diagnosed in one of the nine publicly funded

health care facilities used by residents of the Agincourt HDSS (n=251), had a viral load

137 measurement below 400 copies/mL within seven days of diagnosis (n=29) or migrated into the

138 Agincourt HDSS after their first HIV diagnosis (n=16) were excluded from the analysis to ensure

139 participants were diagnosed and entered HIV care in an Agincourt HDSS facility.

140

### 141 Data source

142 We used data from the Agincourt HDSS-Clinic Link System, previously described, to determine 143 population clinical outcomes (22–25). Briefly, the Clinic Link System is a population-based 144 clinical care database that covers consenting/assenting patients seeking HIV-specific services or 145 chronic care in all nine publicly funded health care facilities used by study area residents. Data 146 typists, stationed at each of the facilities since 2014, consent/assent patients seeking care on a 147 daily basis. After obtaining written informed consent/assent, clinical visit data and patient 148 demographic data are captured in the Clinic Link System and linked to corresponding records in 149 the Agincourt HDSS census database. Data typists continually update clinical records data as 150 individuals return for services.

152	Because the HDSS-Clinic Link System viral load data were occasionally missing, viral load
153	measurements were supplemented using viral load data from the South African National Health
154	Laboratory Service. The South African National Health Laboratory Service provides HIV
155	diagnostic services to approximately 80% of South Africans and conducted more than 5 million
156	viral load tests across 16 laboratories in 2018 (26,27).
157	
158	Mortality and migration data were obtained from the Agincourt HDSS census database and
159	linked to the HDSS-Clinic Link System data. The Agincourt HDSS database has been updated
160	annually since 2000 and provides information on resident status and vital events such as
161	migrations, births, and deaths (17).
162	
163	Measures
164	Linkage to care: Individuals were considered linked to care on the first of the following dates:
165	results delivered for CD4 testing after HIV diagnosis, a follow-up visit with an indication of HIV
166	treatment delivery, or a CD4 or viral load test after HIV diagnosis.
167	
168	Loss to follow-up: Participants with no documented clinic visits for any given 90-day period
169	following diagnosis were considered lost to follow-up (LTFU) on the first date the definition was
170	met (i.e., the 90 <sup>th</sup> day following the most recent visit date). This definition is consistent with a
171	lapse in medication coverage defined in the South African national HIV adherence guidelines
172	(28). We also considered a 180-day clinic visit lapse definition of LTFU. Results from this
173	analysis are presented in the Supplemental Material.
174	

175	Treatment status: Participants were considered on ART the first date of any HIV treatment
176	medication pickup. Individuals who had a suppressed viral load measurement prior to the first
177	recorded ART pickup date (n=3) were considered on ART the same date as the suppressed viral
178	load measurement.
179	
180	Viral suppression status: Viral load measurements less than 400 copies/mL were considered
181	virally suppressed (29,30).
182	
183	Virologic failure: Viral load measurements of 1000 copies/mL and above subsequent to a
184	suppressed viral load measurement were considered indicative of virologic failure (31,32).
185	
186	Suboptimal treatment outcome: Because death (n=1) and virologic failure (n=3) were uncommon
187	in the study population overall, we combined the competing events of LTFU, death, and
188	virologic failure in a "suboptimal treatment outcomes" measure.
189	
190	Statistical analysis
191	To characterize the longitudinal HIV care continuum in the study population we utilized analytic
192	methods similar to those formalized by Lesko et. al (3). These methods are designed to account
193	for competing events and transitions into and out of multiple states over time (2). First, we fit a
194	Fine and Grey sub-distribution proportional hazards models with no covariates and used the
195	Breslow estimator to calculate the cumulative incidence of each of the following care continuum
196	events following diagnosis: suboptimal treatment outcome prior to linkage to care; linkage to
197	care; suboptimal treatment outcome prior to ART initiation (and after linkage to care); ART

198	initiation; suboptimal treatment outcome prior to viral suppression (and after ART initiation);
199	viral suppression; suboptimal treatment outcome following suppression (see S1 Table for
200	additional details and competing events). Date of diagnosis served as the origin for each outcome
201	and administrative censoring occurred on day 365 following diagnosis or February 1, 2019. Once
202	an individual was LTFU, they were not permitted to reenter the study population.
203	
204	We then estimated the proportion of the population in eight mutually exclusive stages of the HIV
205	care continuum at each timepoint following diagnosis (i.e. on any day during the 365 days of
206	follow-up):
207	1) Diagnosed with HIV- not yet linked to care
208	2) Suboptimal treatment outcome before linkage to care
209	3) Linked to care- ART naïve
210	4) Suboptimal treatment outcome after linkage to care but before ART initiation
211	5) On ART- virally non-suppressed
212	6) Suboptimal treatment outcome after ART initiation but before viral suppression
213	7) On ART- virally suppressed
214	8) Suboptimal treatment outcome after suppression
215	This was accomplished by adding and subtracting cumulative incidence curves (see S2 Table for
216	equations). The proportion of individuals in each stage of the continuum is presented as a set of
217	stacked curves that sum to one at each time point by design. The area between adjacent curves
218	represents the restricted (as each participant is followed for a maximum of one year and all
219	outcomes may not be observed) mean time spent in each stage over the one-year follow-up
220	period. Given individuals who were LTFU were not permitted to reenter the study population,

221 estimates of the mean time spent linked to care- ART naïve; on ART- virally non-suppressed; 222 and on ART- virally suppressed, represent the mean time spent in each of these stages with no 223 prior 90-or-more day gap in care. Potential care continuum transitions are specified in the S1 224 Figure. 225 226 Ultimately, we estimated 1) the proportion of participants in each stage of the continuum and 2) 227 the restricted mean time spent in each stage of the continuum over the one-year period following 228 diagnosis in the cohort overall and stratified by treatment era of diagnosis. We used inverse 229 probability of treatment weights to account for meaningful differences in the distribution of sex 230 and age at diagnosis between the two groups. We calculated differences in outcomes among 231 those diagnosed pre- (referent) and post-UTT implementation and estimated the 95% Wald 232 confidence intervals (CI) using the standard error of estimates obtained from 300 non-parametric 233 resamples of the data (33). All analyses were conducted in SAS 9.4 (SAS Institute Inc., Cary, 234 NC). 235 236 Ethics 237 This study was approved by the University of North Carolina at Chapel Hill's Institutional 238 Review Board, the University of the Witwatersrand's Human Research Ethics Committee, and 239 the Mpumalanga Provincial Health Research Committee. 240 241 Results 242 A total of 420 individuals were included. A majority were female (n=389; 92.6%) and diagnosed 243 after the adoption of UTT (n=266; 63.3%) (Table 1). Median age at diagnosis was 22.2

- 244 (interquartile range [IQR]: 20.4-23.7) and median CD4 cell count at diagnosis or entry into care
- 245 was 333 (IQR: 217-458) (Table 1).
- 246

	Total (n=420) n (%)	Pre-UTT (n=154) n (%)	UTT (n=266) n (%)
Sex			
Female	389 (92.6)	146 (94.8)	243 (91.4)
Male	31 (7.4)	8 (5.2)	23 (8.6)
Age at diagnosis (median/IQR)	22.2 (20.4- 23.7)	22.3 (20.7- 23.6)	22.2 (20.3-23.6
CD4 cell count at diagnosis/entry into care	333 (217-458)	329 (200-438)	333.5 (220.5-
(median/IQR) <sup>†</sup>			482.5)
<200 cells/mm <sup>3</sup>	74 (22.5)	32 (24.8)	42 (21.0)
$\geq 200 \text{ cells/mm}^3$	255 (77.5)	97 (75.2)	158 (79.0)

Abbreviations: IQR- interquartile range; UTT- Universal Test and Treat

<sup>\*</sup>missing baseline CD4 n=91

250

At day 90 post-diagnosis, 81.8% of all participants had ever linked to care, 61.6% had ever

252 initiated ART, and 5.9% had ever achieved viral suppression (S2 Figure). Over one-third

253 (33.8%) were LTFU on day 90 (S2 Figure). By 6 and 12 months post-diagnosis, 16.9% and

254 30.9% of all participants had ever achieved viral suppression, respectively (S2 Figure). By the

end of the first year following diagnosis, 68.2% of all participants were LTFU, 0.2% had died,

and 0.7% had experienced virologic failure. Participants spent a mean time of 19.5 days (95%

257 CI: 16.0, 23.0) between diagnosis and linkage to care; 29.4 days (95% CI: 25.6, 33.3) linked to

care but ART-naive; 107.4 days (95% CI: 95.9, 118.8) on ART but virally non-suppressed; and

259 53.7 days (95% CI: 45.2, 62.2) virally suppressed (Table 2).

### 260 Table 2. Time spent in each stage of care continuum over 1-year follow-up period and

	Mean days (95% CI)	Percent (95% CI)
Diagnosed with HIV (not yet linked)	19.5 (16.0, 23.0)	0.1 (0.0, 0.3)
Suboptimal treatment outcome before linkage	49.7 (40.0, 59.4)	18.0 (14.4, 21.7)
Linked to care (ART naïve)	29.4 (25.6, 33.3)	0.0 (0.0, 0.0)
Suboptimal treatment outcome before ART	49.9 (39.9, 59.8)	18.5 (14.8, 22.3)
On ART (non-suppressed)	107.4 (95.9, 118.8)	7.3 (4.5, 10.1)
Suboptimal treatment outcome before suppression	48.8 (40.3, 57.2)	25.0 (20.8, 29.3)
Virally suppressed	53.7 (45.2, 62.2)	23.0 (18.7, 27.3)
Suboptimal treatment outcome after suppression	6.7 (4.1, 9.3)	7.9 (5.3, 10.5)

### 261 percent of individuals in each stage at end of follow-up

262 Abbreviations: ART- antiretroviral therapy; CI- confidence interval; UTT- Universal Test and Treat

264 In weighted analyses, individuals diagnosed in the UTT era initiated ART more quickly after 265 linkage to care (restricted mean time difference [MD] of time between linkage to care and ART 266 initiation: -18.9; 95% CI: -27.3, -10.6), and spent more time over the one-year follow-up period 267 on ART and virally suppressed when compared to those diagnosed in the pre-UTT era (MD of 268 time spent on ART- virally non-suppressed: 12.7; 95% CI: -8.2, 33.7; MD of time spent virally 269 suppressed: 17.7; 95% CI: 1.0, 34.4) (Table 3). Compared to their counterparts, time spent LTFU 270 between diagnosis and linkage to care was greater among those diagnosed in the UTT era while 271 time spent between linkage to care and ART initiation was greater among those diagnosed in the

272 pre-UTT era (Table 3).

<sup>263</sup> 

	Pre-UTT	UTT	Difference in mean
	Mean days (95% CI)	Mean days (95% CI)	days (95% CI)
Crude			
Diagnosed with HIV (not yet linked)	17.3 (11.9, 22.7)	21.4 (16.8, 26.0)	4.1 (-2.9, 11.2)
Suboptimal treatment outcome before linkage	40.8 (26.7, 55.0)	54.7 (42.0, 67.3)	13.8 (-5.0, 32.7)
Linked to care (ART naïve)	41.3 (33.6, 49.0)	22.3 (18.7, 26.0)	-18.9 (-27.3, -10.6)
Suboptimal treatment outcome before ART	66.9 (47.9, 85.9)	40.0 (29.2, 50.8)	-26.9 (-48.7, -5.1)
On ART (non-suppressed)	99.2 (82.2, 116.3)	111.8 (97.6, 125.9)	12.5 (-8.5, 33.5)
Suboptimal treatment outcome before suppression	51.3 (37.4, 65.2)	47.2 (36.3, 58.1)	-4.1 (-21.5, 13.3)
Virally suppressed	43.2 (31.0, 55.5)	59.6 (47.9, 71.3)	16.4 (-0.4, 33.1)
Suboptimal treatment outcome after suppression	4.9 (1.4, 8.4)	8.0 (4.4, 11.5)	3.1 (-1.9, 8.0)
Weighted <sup>†</sup>			
Diagnosed with HIV (not yet linked)	16.9 (11.6, 22.1)	21.3 (16.7, 25.8)	4.4 (-2.5, 11.3)
Suboptimal treatment outcome before linkage	39.8 (26.0, 53.6)	54.0 (41.4, 66.7)	14.2 (-4.3, 32.7)
Linked to care (ART naïve)	41.5 (33.7, 49.3)	22.2 (18.6, 25.9)	-19.3 (-27.7, -10.9)
Suboptimal treatment outcome before ART	66.1 (47.2, 85.1)	39.5 (28.8, 50.2)	-26.6 (-48.3, -5.0)
On ART (non-suppressed)	99.4 (82.4, 116.4)	112.1 (98.0, 126.2)	12.7 (-8.2, 33.7)
Suboptimal treatment outcome before suppression	54.0 (39.4, 68.6)	47.7 (36.7, 58.7)	-6.3 (-24.4, 11.8)
Virally suppressed	42.2 (30.1, 54.4)	59.9 (48.2, 71.6)	17.7 (1.0, 34.4)
Suboptimal treatment outcome after suppression	5.0 (1.4, 8.7)	8.2 (4.5, 11.9)	3.2 (-2.0, 8.4)


273 Table 3. Time spent in each stage of the HIV care continuum over 1-year follow-up period by treatment era of diagnosis

274 Abbreviations: ART- antiretroviral therapy; CI- confidence interval; UTT- Universal Test and Treat

<sup>†</sup>Weighted to account for differences in age at diagnosis and sex by treatment era of diagnosis

276	By the end of follow-up, 85.2% of participants diagnosed in the pre-UTT era had ever linked to
277	care, 60.1% had ever initiated ART, and 26.0% had ever achieved viral suppression (Figure).
278	Among those diagnosed in the UTT era, 80.2% had ever linked to care, 65.7% had ever initiated
279	ART, and 33.3% had ever achieved viral suppression (Figure). On the last day of follow-up,
280	5.7% of participants diagnosed in the pre-UTT era were on ART but non-suppressed, and 19.5%
281	were virally suppressed (Table 4; Figure). Among those diagnosed in the UTT era, 8.5% were on
282	ART but non-suppressed, and 24.5% were virally suppressed (Table 4; Figure). Over 70% of
283	participants diagnosed in the pre-UTT era, as compared to just over 60% in the post-UTT era
284	experienced a suboptimal treatment outcome by the end of the first year following diagnosis with
285	HIV (Table 4; Figure). Suboptimal outcomes between linkage to care and ART initiation were
286	more common among those diagnosed in the pre-UTT versus UTT era by the end of study
287	follow-up and sub-optimal outcomes between diagnosis and linkage to care were more common
288	among those diagnosed in the UTT versus pre-UTT (Table 4; Figure). Approximately 25% of
289	those diagnosed in both the pre-UTT and UTT eras were LTFU between ART initiation and viral
290	suppression (Table 4; Figure).
291	

In analyses using the less restrictive LTFU definition, differences in the restricted mean time
spent in each stage of the care continuum and the proportion in each stage at the end of the oneyear follow-up period were attenuated (S3-5 Tables).



295

### 296 Figure. Cumulative incidence of HIV care outcomes over 1-year following diagnosis, stratified by treatment era

- 297 Abbreviations: ART- antiretroviral treatment; LTFU- lost to follow-up; UTT- Universal Test and Treat
- 298 Weighted to account for differences in age at diagnosis and sex by era of diagnosis

# 299 Table 4. Proportion of participants in each stage of the HIV care continuum 1-year following diagnosis by treatment era of

## 300 diagnosis

	Pre-UTT	UTT	Percent difference
	Percent (95% CI)	Percent (95% CI)	(95% CI)
Crude			
Diagnosed with HIV (not yet linked)	0.4 (0.0, 0.7)	0.2 (0.0, 0.4)	-0.2 (-0.6, 0.3)
Suboptimal treatment outcome before linkage	14.8 (9.6, 20.1)	19.9 (15.2, 24.6)	5.0 (-2.0, 12.0)
Linked to care (ART naïve)	0.0 (-0.1, 0.1)	0.0 (0.0, 0.0)	0.0 (-0.1, 0.1)
Suboptimal treatment outcome before ART	25.2 (18.0-32.4)	14.6 (10.6-18.7)	-10.6 (-18.8, -2.4)
On ART (non-suppressed)	5.8 (2.1, 9.6)	8.5 (4.7, 12.3)	2.6 (-2.5, 7.8)
Suboptimal treatment outcome before suppression	27.2 (20.3-34.1)	23.6 (18.2-28.9)	-3.6 (-12.3, 5.0)
Virally suppressed	20.1 (13.6, 26.5)	24.5 (19.1, 29.9)	4.5 (-3.7, 12.7)
Suboptimal treatment outcome after suppression	6.5 (3.0-10.0)	8.7 (5.2-12.3)	2.2 (-2.7, 7.2)
Weighted <sup>a</sup>			
Diagnosed with HIV (not yet linked)	0.4 (0.0, 0.7)	0.2 (0.0, 0.4)	-0.2 (-0.6, 0.3)
Suboptimal treatment outcome before linkage	14.5 (9.3-19.6)	19.6 (14.9-24.3)	5.2 (-0.2, 12.0)
Linked to care (ART naïve)	0.0 (-0.1, 0.1)	0.0 (0.0, 0.0)	0.0 (-0.1, 0.1)
Suboptimal treatment outcome before ART	25.0 (17.8-32.2)	14.4 (10.4-18.5)	-10.6 (-18.8, -2.4)
On ART (non-suppressed)	5.7 (2.0, 9.4)	8.5 (4.7, 12.3)	2.8 (-2.3, 7.9)
Suboptimal treatment outcome before suppression	28.4 (21.3-35.5)	23.9 (18.5-29.2)	-4.5 (-13.4, 4.4)
Virally suppressed	19.5 (13.1, 25.9)	24.5 (19.1, 29.9)	5.0 (-3.1, 13.1)
Suboptimal treatment outcome after suppression	6.5 (3.0-10.1)	8.9 (5.2-12.5)	2.3 (-2.7, 7.4)

301 Abbreviations: UTT- Universal Test and Treat; ART- antiretroviral therapy; CI- confidence interval

302 <sup>†</sup>Weighted to account for differences in age at diagnosis and sex by treatment era of diagnosis

# 304 **Discussion**

305	This study characterizes longitudinal HIV care continuum outcomes among YLHIV newly
306	initiating HIV care in nine publicly funded health care facilities in rural South Africa pre- and
307	post-implementation of the UTT policy. Overall, 82% of individuals had linked to care, 63% had
308	initiated ART, and 31% had achieved viral suppression by one year following diagnosis. There
309	were modest improvements in time spent on ART and virally suppressed among YLHIV
310	diagnosed after the adoption of the UTT policy. However, the proportion of individuals
311	diagnosed in the UTT era who had initiated ART, were retained in care, and were virally
312	suppressed one year following diagnosis was well below the Joint United Nations' Programme
313	on HIV/AIDS' 95-95-95 goal. A substantial proportion of individuals diagnosed in the UTT era
314	disengaged from care in the periods between diagnosis and linkage to care and ART initiation
315	and viral suppression.
316	
317	Approximately 66% of individuals diagnosed during the UTT era initiated ART in the first year
318	following diagnosis. The mean time spent suppressed during this period was 60 days and just
319	25% of individuals were suppressed at the end of follow-up. This represents a substantial gap in

320 sustained retention on ART and viral suppression among YLHIV diagnosed in the era of UTT

321 that must be urgently addressed.

322

323 Implementation of UTT appeared to influence the timing of care disengagement among YLHIV 324 in this study. Specifically, those diagnosed in the pre-UTT era were more likely to be LTFU 325 between linkage to care and ART initiation while those diagnosed in the UTT era were more 326 likely to be LTFU between diagnosis and linkage to care. This suggests individuals diagnosed

327 during the UTT era may have been less likely to return to care to start ART if they were not 328 initiated the same day they were diagnosed. Existing evidence suggests low ART readiness may 329 impede retention in care following diagnosis in the UTT era (34). For example, a study of adults 330 immediately referred for ART in South Africa found that individuals who did not expect to 331 receive a positive HIV diagnosis had significantly lower odds of ART readiness than others 332 (adjusted odds ratio 0.26; 95% CI: 0.09, 0.78) and that the odds of linkage to care among those 333 expressing treatment readiness were 2.97 times that in individuals who were not ready to initiate 334 ART (34,35).

335

336 These findings have important implications for HIV policy and programming for South African 337 YLHIV in the UTT era. First, improved counseling and linkage to care at the point of diagnosis 338 with HIV may be critical to the success of same-day ART initiation policies. Second, increased 339 resources in the UTT era should be spent on retention in care efforts for YLHIV, particularly in 340 the periods between diagnosis and linkage to care and ART initiation and viral suppression. 341 Longitudinal counseling following diagnosis has been shown to improve linkage to care in other 342 settings across sub-Saharan Africa (36,37). For example, in a cluster randomized controlled trial 343 exploring the effects of a counseling intervention on treatment outcomes among people living 344 with HIV in Uganda, those in the intervention arm were significantly more likely to link to care 345 compared to those in the control arm (37). Differentiated, youth-friendly medical care and 346 programs that target improvements in young people's self-esteem, social support, and overall 347 psychosocial well-being may also be important to improving care outcomes for YLHIV (38–44). 348 A retrospective cohort study of youth initiating ART at 37 facilities in South Africa 349 demonstrated just 19% of study participants receiving support services were non-suppressed 5-

350 years after ART initiation compared to 37% of those who did not receive community based-

- 351 services (44). Care models such as these should be prioritized for South African YLHIV
- 352 particularly in the critical first year following diagnosis.
- 353

354 Increased attention must also center on monitoring care services for this group, specifically.

355 While the cross-sectional HIV care cascade (45) is useful in describing the proportion of

individuals in each stage of the care continuum at a specific point in time, it provides a mere

357 snapshot of the true patient experience (2,46). Longitudinal HIV care cascades allow for a

nuanced exploration of population-level outcomes over time (1,2) and can aid in assessing the

359 effectiveness of HIV care programs as individuals progress through each stage of the continuum.

360 Ultimately, these cascades can be harnessed to identify specific gaps in treatment and care

361 services at precise time points following diagnosis (1,3).

362

363 This analysis had limitations. First, viral load monitoring is recommended just once per year 364 under the South African National HIV Treatment guidelines (28). Because we were primarily 365 interested in assessing HIV treatment outcomes in the first year following an individual's 366 diagnosis, most participants had one opportunity to achieve viral suppression during the study 367 period. Among those who achieved viral suppression, true time to viral suppression may have 368 been shorter but went uncaptured because of infrequent viral load monitoring. Similarly, 369 virologic failure among individuals who achieved suppression may have been under-captured 370 due to infrequent viral load monitoring. Misclassified person-time could subsequently result in 371 biased effect estimates. Second, mortality and migration data were only accessible from 2014-372 2017. Individuals who died in 2018 and were not yet administratively censored or LTFU before

373	the time of de	ath would have misclassified person-time. Given just one participant died in the					
374	2014-2017 follow-up period, this was a minor concern. Lastly, the nature of the Clinic Link						
375	System prevented us from reliably ascertaining the reason for individuals' LTFU. It is possible						
376	that individua	ls who were classified as LTFU transferred into care at a clinic outside the nine					
377	included healt	h care facilities, as documented in other studies (24,25). Individuals who					
378	transferred car	re and were classified as LTFU may have progressed through additional stages in					
379	the HIV care continuum during the one-year follow-up period, though we do not expect						
380	differential migration with respect to treatment era.						
381							
382	Conclusion	8					
383	Implementatio	on of the World Health Organization's UTT policy yielded modest improvements					
384	in the time spe	ent on ART and virally suppressed among South African YLHIV. However, with					
385	just 66% of Y	LHIV diagnosed in the UTT era initiating ART, and just 25% virally suppressed					
386	one year follo	wing diagnosis, meeting UNAIDS 95-95-95 targets remains a challenge. HIV					
387	treatment prog	grams and policies for YLHIV in the UTT era should specifically center on					
388	improving lon	ngitudinal care outcome monitoring and retention in care in the periods immediately					
389	following diagnosis and ART initiation.						
390							
391	Abbreviatio	ons					
392	ART	anti-retroviral therapy					
393	HDSS	Health and Socio-Demographic Surveillance System study area					
394	HIV	human-immunodeficiency virus					
395	LTFU	lost-to follow-up					

- 396 UNAIDS United Nations' Joint Programme on HIV/AIDS
- 397 UTT Universal Test and Treat policy
- 398 YLHIV youth living with HIV
- 399

## 400 **Declarations**

### 401 Ethics approval and consent to participate

- 402 This study was approved by the University of North Carolina at Chapel Hill's Institutional
- 403 Review Board, the University of the Witwatersrand's Human Research Ethics Committee, and
- 404 the Mpumalanga Provincial Health Research Committee. All individuals provided written
- 405 informed consent or assent for inclusion of their electronic health records in the Agincourt-
- 406 HDSS Clinic Link System.
- 407 **Consent for publication**
- 408 Not applicable.

### 409 Availability of data and materials

410 The datasets analyzed during the current study are not publicly available due to the sensitive nature

411 of HIV treatment and care data. Data may be made available from the study team on reasonable

412 request.

## 413 Competing interests

- 414 Funding acknowledgments are listed below under the "Funding" section. The authors declare
- 415 that they have no other competing interests.
- 416 Funding
- 417 Author LMF was supported in part by ViiV Healthcare, NIH Research Training Grant # D43
- 418 TW009340 funded by the Fogarty International Center, NINDS, NIMH, and NHBLI, and NIMHD

419 grant T37 MD014218; author JKE was supported in part by NIH award # K01AI125087 funded 420 by NIAID; additional funding for this project was provided in part by the American people through 421 the President's Emergency Plan for AIDS Relief (PEPFAR) and United States Agency for 422 International Development (USAID) under the Cooperative Agreement Project SOAR 423 (Supporting Operational AIDS Research), # AID-OAA-14-00060 and the Department of Science 424 and Innovation, the University of the Witwatersrand, and the Medical Research Council, South 425 Africa. The content of this publication is the sole responsibility of the authors and does not 426 necessarily reflect the views or policies of the U.S. Agency for International Development, 427 PEPFAR, or the National Institutes of Health, and does not imply endorsement by the U.S. 428 Government.

### 429 Authors contributions

430 LMF- Conceptualization; Funding; Project administration; Data curation; Formal analysis;

431 Methodology; Writing- original draft; JKE- Conceptualization; Methodology; Writing- revising

432 & editing; NM-Project administration; Data curation; Writing- revising & editing; FXGO-

433 Project administration; Methodology; Writing- revising & editing; NH- Funding; Writing-

434 revising & editing; BP- Methodology; Writing- revising & editing; AM- Methodology; Writing-

435 revising & editing; KM- Methodology; Writing- revising & editing; CWK- Data curation;

436 Project administration; Writing- revising & editing; MKD- Data curation; Writing- revising &

437 editing; SAL- Funding; Methodology; Writing- revising & editing; KK- Funding; Methodology;

438 Project administration; Writing- revising & editing; AP- Conceptualization; Funding;

439 Methodology; Writing- revising & editing.

#### 440 Acknowledgments

441 The authors would like to thank all the individuals who participated in this study.

442

# 443 **References**

- 444 1. Jose S, Delpech V, Howarth A, Burns F, Hill T, Porter K, et al. A continuum of HIV care
- describing mortality and loss to follow-up: a longitudinal cohort study. The Lancet HIV.
- 446 2018 Jun 1;5(6):e301–8.
- 447 2. Mody A, Glidden D v, Eshun-Wilson I, Sikombe K, Simbeza S, Mukamba N, et al.
- 448 Longitudinal Care Cascade Outcomes Among People Eligible for Antiretroviral Therapy
- 449 Who Are Newly Linking to Care in Zambia: A Multistate Analysis. Clinical Infectious
- 450 Diseases [Internet]. 2020 Dec 17 [cited 2021 Feb 11];71(10):e561–70. Available from:
- 451 https://academic.oup.com/cid/article/71/10/e561/5805511
- 452 3. Lesko CR, Edwards JK, Moore RD, Lau B. A longitudinal, HIV care continuum: 10-year
- 453 restricted mean time in each care continuum stage after enrollment in care, by history of
- 454 IDU. AIDS [Internet]. 2016 [cited 2019 Oct 3];30(14):2227–34. Available from:
- 455 http://www.ncbi.nlm.nih.gov/pubmed/27314178
- 456 4. Beer L, Mattson CL, Bradley H, Shouse RL. Trends in ART prescription and viral
- 457 suppression among HIV-positive young adults in care in the United States, 2009-2013.
- 458 Journal of Acquired Immune Deficiency Syndromes. 2017 Sep 1;76(1):e1–6.
- 459 5. Lee S, Kapogiannis BG, Allison S. Improving the youth HIV prevention and care
- 460 continuums: The adolescent medicine trials network for HIV/AIDS interventions. Vol. 8,
- 461 JMIR Research Protocols. JMIR Publications Inc.; 2019.
- 462 6. Zanoni BC, Mayer KH. The Adolescent and Young Adult HIV Cascade of Care in the
- 463 United States: Exaggerated Health Disparities. AIDS Patient Care and STDs. 2014 Mar

464 1;28(3):128–35.

465	7.	Enane LA, Davies MA, Leroy V, Edmonds A, Apondi E, Adedimeji A, et al. Traversing
466		the cascade: urgent research priorities for implementing the "treat all" strategy for children
467		and adolescents living with HIV in sub-Saharan Africa. Journal of Virus Eradication.
468		2018;4(Suppl 2):40–6.
469	8.	UNAIDS. Ending the AIDS epidemic for adolescents, with adolescents. Geneva,
470		Switzerland; 2016. 2030 p.
471	9.	Slogrove AL, Sohn AH. The global epidemiology of adolescents living with HIV: Time
472		for more granular data to improve adolescent health outcomes. Vol. 13, Current Opinion
473		in HIV and AIDS. Lippincott Williams and Wilkins; 2018. p. 170-8.
474	10.	Zanoni BC, Archary M, Buchan S, Katz IT, Haberer JE. Systematic review and meta-
475		analysis of the adolescent HIV continuum of care in South Africa: the Cresting Wave.
476		BMJ Global Health. 2016;1(e000004).
477	11.	Pillay Y, Pillay A. Implementation of the Universal Test and Treat strategy for HIV
478		positive patients and differentiated care for stable patients. Pretoria, South Africa; 2016.
479	12.	Lippman SA, El Ayadi AM, Grignon JS, Puren A, Liegler T, Venter WDF, et al.
480		Improvements in the South African HIV care cascade: findings on 90-90-90 targets from
481		successive population-representative surveys in North West Province. J Int AIDS Soc.
482		2019 Jun 1;22(6).
483	13.	Onoya D, Hendrickson C, Sineke T, Maskew M, Long L, Bor J, et al. Attrition in HIV
484		care following HIV diagnosis: a comparison of the pre-UTT and UTT eras in South

485 Africa. J Int AIDS Soc. 2021 Feb 1;24(2).

486	14.	Pettifor A	Filiatreau L	Delany	v-Moretlwe S.	Time to	strengthen HIV	<sup>7</sup> treatment an

- 487 prevention for youth. The Lancet HIV [Internet]. 2019 Oct [cited 2019 Oct 5];6(11).
- 488 Available from: https://linkinghub.elsevier.com/retrieve/pii/S2352301819302322
- 489 15. Davies MA, Pinto J. Targeting 90-90-90 Don't leave children and adolescents behind. J
- 490 Int AIDS Soc. 2015;18(Suppl 6):20745.
- 491 16. Gleeson HS, Oliveras Rodriguez CA, Hatane L, Hart D. Ending AIDS by 2030: The
- 492 importance of an interlinked approach and meaningful youth leadership: The. J Int AIDS493 Soc. 2018;21:e25061.
- 494 17. Kahn K, Collinson MA, Xavier Gómez-olivé F, Mokoena O, Twine R, Mee P, et al.
- 495 Profile: Agincourt health and socio-demographic surveillance system. International

496 Journal of Epidemiology. 2012 Aug 1;41(4):988–1001.

497 18. MRC/Wits Agincourt Research Unit. Research Findings – MRC/Wits Agincourt Unit

498 [Internet]. 2014 [cited 2019 May 31]. Available from:

- 499 https://www.agincourt.co.za/?page\_id=1911
- 500 19. Gómez-Olivé FX, Angotti N, Houle B, Klipstein-Grobusch K, Kabudula C, Menken J, et
- al. Prevalence of HIV among those 15 and older in rural South Africa. AIDS Care -
- 502 Psychological and Socio-Medical Aspects of AIDS/HIV. 2013;25(9):1122–8.
- 503 20. Collinson MA, White MJ, Bocquier P, McGarvey ST, Afolabi SA, Clark SJ, et al.
- 504 Migration and the epidemiological transition: Insights from the Agincourt sub-district of 505 northeast South Africa. Global Health Action. 2014;7(SUPP.1).
- 506 21. West R, Leslie H, Gómez-Olivé FX, Kahn K, Twine R, Filiatreau L, et al. Using multiple

507 modes of assessment to measure patient experience in public clinics in rural Mpumalanga,

508 South Afria. In: South African AIDS Conference. Durban, South Africa; 2019.

509 22. Kabudula CW, Clark BD, Gómez-Olivé FX, Tollman S, Menken J, Re	509 - 2.	9 22. Ka	idudula CW.	Clark BD.	Gomez-Onve FA.	Tonman S.	. Menken J.	. Remers v	J. The
--	----------	----------	-------------	-----------	----------------	-----------	-------------	------------	--------

- 510 promise of record linkage for assessing the uptake of health services in resource
- 511 constrained settings: a pilot study from South Africa. BMC Medical Research
- 512 Methodology. 2014 Dec 24;14(1):71.
- 513 23. Lippman SA, Pettifor A, Rebombo D, Julien A, Wagner RG, Kang Dufour MS, et al.
- 514 Evaluation of the Tsima community mobilization intervention to improve engagement in
- 515 HIV testing and care in South Africa: Study protocol for a cluster randomized trial.
- 516 Implementation Science. 2017 Jan 17;12(1):1–13.
- 517 24. Etoori D, Gomez-Olive FX, Reniers G, Rice B, Renju J, Kabudula CW, et al. Outcomes
- 518 After Being Lost to Follow-up Differ for Pregnant and Postpartum Women When
- 519 Compared With the General HIV Treatment Population in Rural South Africa. J Acquir
- 520 Immune Defic Syndr [Internet]. 2020 Oct 1 [cited 2021 Aug 31];85(2):127–37. Available
- 521 from: /pmc/articles/PMC7495979/
- 522 25. Etoori D, Wringe A, Kabudula CW, Renju J, Rice B, Gomez-Olive FX, et al.
- 523 Misreporting of Patient Outcomes in the South African National HIV Treatment Database:
- 524 Consequences for Programme Planning, Monitoring, and Evaluation. Frontiers in Public
- 525 Health. 2020 Apr 7;8:100.
- 526 26. Sherman GG, Mazanderani AH, Barron P, Bhardwaj S, Niit R, Okobi M, et al. Toward
- 527 elimination of mother-to-child transmission of HIV in South Africa: How best to monitor
- 528 early infant infections within the Prevention of Mother-to-Child Transmission Program.
- 529 Journal of Global Health. 2017 Apr 12;7(1).

530	27.	Girdwood SJ,	Crompton T	Sharma M.	Dorward J.	Garrett N	, Drain PK,	et al. Cost-

- 531 effectiveness of adoption strategies for point of care HIV viral load monitoring in South
- 532 Africa. EClinicalMedicine. 2020 Nov 1;28:100607.
- 533 28. Department of Health Republic of South Africa. Adherence Guidelines for HIV, TB and
- 534 NCDs. Policy and service guidelines for linkage to care, adherence to treatment and
- 535 retention in care [Internet]. Pretoria, South Africa; 2016 [cited 2020 Sep 2]. Available
- 536 from: https://www.nacosa.org.za/wp-content/uploads/2016/11/Integrated-Adherence-
- 537 Guidelines-NDOH.pdf
- 538 29. Moosa A, Gengiah TN, Lewis L, Naidoo K. Long-term adherence to antiretroviral therapy
- in a South African adult patient cohort: a retrospective study. BMC Infect Dis. 2019 Sep
  5;19(1):775.
- 541 30. Kharsany ABM, Cawood C, Lewis L, Yende-Zuma N, Khanyile D, Puren A, et al. Trends
- in HIV Prevention, Treatment, and Incidence in a Hyperendemic Area of KwaZulu-Natal,

543 South Africa. JAMA Netw Open. 2019 Nov 1;2(11):e1914378.

- 544 31. Kiweewa F, Esber A, Musingye E, Reed D, Crowell TA, Cham F, et al. HIV virologic
- 545 failure and its predictors among HIV-infected adults on antiretroviral therapy in the

546 African Cohort Study. PLoS ONE. 2019 Feb 1;14(2):e0211344.

- 547 32. Laprise C, De Pokomandy A, Baril JG, Dufresne S, Trottier H. Virologic failure following
- persistent low-level viremia in a cohort of HIV-positive patients: Results from 12 years of
  observation. Clinical Infectious Diseases. 2013 Nov 15;57(10):1489–96.
- 550 33. Efron B, Tibshirani R. An Introduction to the Bootstrap. 1st ed. Chapman and Hall/CRC;
  551 1994.

552	34.	Maughan-Brown B, Harrison A, Galárraga O, Kuo C, Smith P, Bekker LG, et al. Factors
553		affecting linkage to HIV care and ART initiation following referral for ART by a mobile
554		health clinic in South Africa: evidence from a multimethod study. Journal of Behavioral
555		Medicine. 2019 Oct 1;42(5):883-97.
556	35.	Maughan-Brown B, Smith P, Kuo C, Harrison A, Lurie MN, Bekker LG, et al. Readiness
557		for Antiretroviral Therapy: Implications for Linking HIV-Infected Individuals to Care and
558		Treatment. AIDS and Behavior. 2018 Mar 1;22(3):691–700.
559	36.	Herce ME, Chi BH, Liao RC, Hoffmann CJ. Re-thinking Linkage to Care in the Era of
560		Universal Test and Treat: Insights from Implementation and Behavioral Science for
561		Achieving the Second 90. AIDS and Behavior [Internet]. 2019 Sep 1 [cited 2021 Feb
562		26];23(2):120-8. Available from: https://doi.org/10.1007/s10461-019-02541-5
563	37.	Ruzagira E, Grosskurth H, Kamali A, Baisley K. Brief counselling after home-based HIV
564		counselling and testing strongly increases linkage to care: A cluster-randomized trial in
565		Uganda. J Int AIDS Soc [Internet]. 2017 Oct 1 [cited 2021 Feb 26];20(2):e25014.
566		Available from: http://doi.wiley.com/10.1002/jia2.25014
567	38.	Willis N, Napei T, Armstrong A, Jackson H, Apollo T, Mushavi A, et al. Zvandiri-
568		Bringing a Differentiated Service Delivery Program to Scale for Children, Adolescents,
569		and Young People in Zimbabwe. J Acquir Immune Defic Syndr [Internet]. 2018 [cited
570		2019 Sep 28];78 Suppl 2:S115–23. Available from:
571		http://www.ncbi.nlm.nih.gov/pubmed/29994833
572	39.	Reif LK, McNairy ML, Lamb MR, Fayorsey R, Elul B. Youth-friendly services and
573		differentiated models of care are needed to improve outcomes for young people living

574 with HIV. Current Opinion in HIV and AIDS [Internet]. 2018 May 1 [cite
--

- 575 21];13(3):249–56. Available from: https://pubmed.ncbi.nlm.nih.gov/29432230/
- 576 40. Ruria EC, Masaba R, Kose J, Woelk G, Mwangi E, Matu L, et al. Optimizing linkage to
- 577 care and initiation and retention on treatment of adolescents with newly diagnosed HIV
- 578 infection. AIDS [Internet]. 2017 Jul 1 [cited 2021 Jan 6];31:S253–60. Available from:
- 579 http://journals.lww.com/00002030-201707013-00008
- 580 41. Lamb MR, Fayorsey R, Nuwagaba-Biribonwoha H, Viola V, Mutabazi V, Alwar T, et al.
- 581 High attrition before and after ART initiation among youth (15–24 years of age) enrolled
- 582 in HIV care. AIDS [Internet]. 2014 Feb 20 [cited 2018 Jan 26];28(4):559–68. Available
- from: http://www.ncbi.nlm.nih.gov/pubmed/24076661
- 584 42. Bhana A, Mellins CA, Petersen I, Alicea S, Myeza N, Holst H, et al. The VUKA family
- 585 program: piloting a family-based psychosocial intervention to promote health and mental
- health among HIV infected early adolescents in South Africa. AIDS Care [Internet]. 2014
- 587 Jan [cited 2018 Jan 27];26(1):1–11. Available from:
- 588 http://www.ncbi.nlm.nih.gov/pubmed/23767772
- 589 43. Casale M, Carlqvist A, Cluver L. Recent Interventions to Improve Retention in HIV Care
- and Adherence to Antiretroviral Treatment Among Adolescents and Youth: A Systematic
- 591 Review. AIDS Patient Care and STDs [Internet]. 2019 Jun 1 [cited 2021 Aug
- 592 3];33(6):237. Available from: /pmc/articles/PMC6588099/
- 593 44. Fatti G, Jackson D, Goga AE, Shaikh N, Eley B, Nachega JB, et al. The effectiveness and
- 594 cost-effectiveness of community-based support for adolescents receiving antiretroviral
- 595 treatment: An operational research study in South Africa. J Int AIDS Soc [Internet]. 2018

596	Feb 1 [cited 2020 Dec 30];21(Suppl Suppl 1). Available from:

- 597 https://pubmed.ncbi.nlm.nih.gov/29485714/
- 598 45. Gardner EM, McLees MP, Steiner JF, del Rio C, Burman WJ. The spectrum of
- 599 engagement in HIV care and its relevance to test-and-treat strategies for prevention of
- 600 HIV infection. Clinical Infectious Diseases [Internet]. 2011 Mar 15 [cited 2017 Sep
- 601 17];52(6):793–800. Available from: https://academic.oup.com/cid/article-
- 602 lookup/doi/10.1093/cid/ciq243
- 46. Nash D, Robertson MK. How to Evolve the Response to the Global HIV Epidemic With
- New Metrics and Targets Based on Pre-Treatment CD4 Counts [Internet]. Vol. 16,
- 605 Current HIV/AIDS Reports. Current Medicine Group LLC 1; 2019 [cited 2021 Feb 16]. p.
- 606 304–13. Available from: https://pubmed.ncbi.nlm.nih.gov/31278620/
- 607

### 608 Additional Files

- 609 S1 Table: Events of interest in longitudinal HIV care continuum
- 610 S2 Table: Equations for estimating the proportion of individuals in each stage of the continuum
- 611 at any given time point during study follow-up
- 612 S1 Figure: Framework for flow through the longitudinal HIV care continuum
- 613 S2 Figure. Cumulative incidence of HIV care outcomes over the 1-year follow-up period in
- 614 study population overall
- 615 S3 Table. Time spent in each stage of care continuum over 1-year follow-up period and percent
- 616 of individuals in each stage at end of follow-up<sup>a</sup>
- 617 S4 Table. Time spent in each stage of the HIV care continuum over 1-year follow-up period by
- 618 treatment era of diagnosis<sup>a</sup>

- 619 S5 Table. Proportion of participants in each stage of the HIV care continuum 1-year following
- 620 diagnosis by treatment era of diagnosis<sup>a</sup>